康寧傑瑞製藥-B(09966.HK)展示兩項藥物研究成果
康寧傑瑞製藥-B(09966.HK)公布,KN046及KN026的研究成果於2023年歐洲腫瘤內科學會大會上展示,該大會是一個具影響力的歐洲腫瘤學平台。
公司指,KN046聯合阿昔替尼的耐受性良好,在一線治療晚期非小細胞肺癌中顯示良好的療效及安全性,正進行第二階段入組受試,並計劃對一線非小細胞肺癌患者進行III期隨機臨床試驗,以確認KN046聯合阿昔替尼無化療方案的可行性。至於KN026聯合多西他賽,用於人表皮生長因子受體2陽性早期或局部晚期乳腺癌患者的新輔助治療,顯示出良好的臨床效果,具有可接受和可控的安全性。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.